ABERNETHY MATT 4

What Happened

• Matt Abernethy, a non‑employee director of Fate Therapeutics (FATE), was granted options covering 87,900 shares on June 12, 2026. The Form 4 reports the acquisition as $0 (an equity award/option grant), not a cash purchase or sale. This is a grant of derivative securities (options), not an exercised or sold position.

Key Details

• Transaction date: June 12, 2026; Form 4 filed June 15, 2026 (filing appears timely).
• Reported amount: 87,900 options (acquisition code A); acquisition price shown as $0.00 (award/grant).
• Vesting: Options vest and become exercisable on the earlier of (i) June 12, 2027 or (ii) the 2027 Annual Meeting of Stockholders, contingent on continued board service (footnote).
• Shares owned after the transaction: not specified in the provided excerpt.
• Footnotes: Grant made under the Issuer’s Amended and Restated Non‑Employee Director Compensation Policy (annual director equity grant).

Context

• This is a routine director compensation grant — an award of options rather than a cash purchase or sale. Options typically require vesting and an exercise to convert into stock; nothing in this filing indicates exercise or an immediate sale.
• Such grants are common for non‑employee directors and are compensation for board service; they do not, by themselves, indicate buying or selling sentiment.
• If you track insider activity, note this is a derivative grant (options) with a one‑year vesting trigger (or tied to the next annual meeting) and not an immediate change in market exposure.